Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Botulinum neurotoxin type A (peripherally acting muscle relaxant)

IncobotulinumtoxinA

XEOMIN COSMETIC

Dosage form
Tablet
Available strengths
100 units per vial
Drug class
Botulinum neurotoxin type A (peripherally acting muscle relaxant)
Common brand
XEOMIN COSMETIC

Clinical overview. IncobotulinumtoxinA (brand name XEOMIN COSMETIC) is a purified botulinum toxin type A injection given by a physician to temporarily improve the appearance of glabellar lines, horizontal forehead lines, and lateral canthal lines (crow's feet) in adults. It works by temporarily relaxing the small facial muscles responsible for these lines, with treatments generally spaced at least 3 months apart. It carries a boxed warning that the toxin's effect can rarely spread beyond the injection site, causing swallowing or breathing difficulty that has, in rare cases, been fatal.

Indication

Common therapeutic uses

  • IncobotulinumtoxinA (XEOMIN COSMETIC) is used in adults for the temporary improvement in the appearance of moderate to severe horizontal forehead lines, lateral canthal lines ("crow's feet"), and glabellar lines (frown lines between the eyebrows).
  • It must only be given by a physician with appropriate qualifications and experience in botulinum toxin injection technique.

Pregnancy

Risk assessment and monitoring considerations

  • IncobotulinumtoxinA should not be used during pregnancy.
  • It has not been studied in pregnant women, and animal studies have shown reproductive toxicity; the potential risk to a human fetus is unknown.

Breastfeeding

Infant exposure considerations

  • It is not known whether incobotulinumtoxinA passes into human breast milk.
  • Because of this unknown risk, its use is not recommended while breastfeeding.

Geriatrics

Dosing and tolerability considerations

  • Clinical data in patients over 65 years of age are limited, since no trials were specifically designed for this age group.
  • Treatment in older adults should begin at the lowest recommended dose for the specific area being treated, with cautious dose adjustment.

Pediatrics

Use in children and adolescents

  • IncobotulinumtoxinA (XEOMIN COSMETIC) has not been studied in patients under 18 years of age and is not recommended for use in this age group.

Dosage & Administration

Practical dosing and administration

  • For glabellar lines, the recommended dose is 20 units, injected in 4-unit amounts across 5 sites: two injections into each corrugator muscle and one into the procerus muscle.
  • For lateral canthal lines, the recommended dose is 12 units per side (24 units total), divided across either 3 or 4 injection points per eye area depending on the technique used.
  • For horizontal forehead lines, the recommended dose range is 10 to 20 units, injected across 5 horizontally spaced sites in the frontalis muscle, at least 2 cm above the eyebrows.
  • Treatment sessions should not be repeated more often than every 3 months.
  • The product must be reconstituted with preservative-free sterile saline before use, and any reconstituted solution not used within 24 hours (refrigerated) must be discarded.
  • Injections must be given into muscle only (intramuscular), using a fine needle, by a physician trained in the technique.
  • A single vial should not be used for more than one treatment session or more than one patient, since the product contains no preservative.
  • Formal missed-dose guidance does not apply, since treatment is scheduled and administered by a physician rather than self-dosed on a fixed regimen.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Overdose effects depend on the dose and injection site, and symptoms may not appear immediately after injection.
  • Excess toxin can cause muscle weakness or paralysis spreading beyond the injected area.
  • Drooping eyelid (ptosis) and double vision (diplopia) may occur.
  • Breathing and speech difficulties can develop, including paralysis of the respiratory or swallowing muscles, which may lead to aspiration pneumonia.
  • Management is symptomatic and includes medical monitoring for excessive muscle weakness or paralysis for up to several weeks, with assisted ventilation if the respiratory muscles are affected.

Common side effects

Frequently reported tolerability concerns

  • Headache is common.
  • Pain, bruising, redness, or swelling at the injection site may occur.
  • Drooping of the eyelid (ptosis) may occur.
  • Swelling of the eyelid may occur.
  • Dry eye or excess tearing may occur.
  • Facial or eyebrow asymmetry may occur.
  • A heavy or tight feeling in the treated area may occur.
  • Numbness or altered sensation near the injection site may occur.
  • Blurred vision may occur.
  • Nasopharyngitis (common cold-type symptoms) may occur.
  • Nausea may occur.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • The effects of the toxin can spread beyond the injected area to other parts of the body, causing symptoms such as generalized muscle weakness, drooping eyelids, double vision, trouble speaking, or difficulty breathing and swallowing; these can appear hours to weeks after injection and have rarely been fatal.
  • Serious hypersensitivity reactions, including anaphylaxis, serum sickness, hives, tissue swelling, and difficulty breathing, have been reported rarely.
  • Drooping of the eyebrow (brow ptosis) can occur, and in the combined treatment of multiple facial areas at once, the risk of toxin spreading beyond the treated muscles is higher.
  • Speech and swallowing difficulty have been reported when multiple facial areas were treated together.
  • Muscle wasting (atrophy) near the treated area has been reported after repeated use.
  • Development of antibodies against the toxin can occur with frequent or high-dose treatment, potentially leading to treatment failure.
  • Seek urgent medical attention for any trouble breathing, swallowing, or speaking after treatment, since this can signal spread of the toxin's effect beyond the injection site.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with a bleeding disorder or those taking blood-thinning medication, given the risk of bruising or bleeding at the injection site.
  • Not recommended in patients with a history of difficulty swallowing or inhaling food or liquid into the airway (aspiration).
  • Use with caution in patients with amyotrophic lateral sclerosis (ALS) or other conditions affecting the nerves and muscles.
  • Use with caution when injecting muscles that are already notably weak or thinned (atrophied).
  • Avoid injecting near the muscle that lifts the eyelid, and keep injections in the central corrugator muscle at least 1 cm above the bony eyebrow ridge, to reduce the risk of eyelid drooping.
  • Avoid injections too close to the muscle that lifts the corner of the mouth, to reduce the risk of lip drooping when treating lines near the eyes.
  • If injection sites are marked on the skin with a pen, the injection should not go through the ink marks, since this can cause a permanent tattoo-like mark.
  • Avoid driving or operating machinery if weakness, vision changes, dizziness, or eyelid drooping occur after treatment.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to botulinum toxin type A or to any ingredient in the formulation.
  • Contraindicated in patients with a generalized disorder of muscle activity, such as myasthenia gravis or Lambert-Eaton syndrome.
  • Contraindicated in patients with an infection or inflammation at the planned injection site.

Drug interactions

Clinically relevant combinations

  • Aminoglycoside antibiotics and spectinomycin may theoretically strengthen the muscle-weakening effect of botulinum toxin and should be used with special care in combination.
  • Other drugs that interfere with nerve-to-muscle transmission, such as tubocurarine-type muscle relaxants, may add to the effects of incobotulinumtoxinA.
  • If a peripheral muscle relaxant is needed after treatment, the starting dose may need to be reduced, or a shorter-acting relaxant used instead of a longer-acting one.
  • 4-aminoquinoline drugs, such as chloroquine or hydroxychloroquine, may reduce the effectiveness of incobotulinumtoxinA.
  • No formal drug-drug interaction studies have been conducted with incobotulinumtoxinA.

Food interactions

Meal-related administration

  • IncobotulinumtoxinA is given by intramuscular injection, so food interactions do not apply to this medication.

Time of administration

Practical scheduling

  • Treatment is given in-office by a physician at scheduled intervals of no more often than every 3 months; food timing does not apply to this injectable treatment.

Storage

Product handling

  • Store unreconstituted vials at room temperature, up to 25°C, and do not use after the expiry date.
  • Once reconstituted, the solution should ideally be used right away, but may be stored refrigerated at 2°C to 8°C for up to 24 hours; do not freeze it.
  • Any unused reconstituted product or leftover material must be inactivated with a disinfecting solution before disposal.

Patient take-away

Key counselling points for a quick closing summary

  • IncobotulinumtoxinA (XEOMIN COSMETIC) is a botulinum toxin injection used to temporarily reduce the appearance of frown lines, forehead lines, and crow's feet.
  • It must be given by a qualified physician, and treatments are generally spaced at least 3 months apart.
  • Common effects include headache and temporary bruising, swelling, or drooping near the injection site.
  • Seek urgent medical attention for any difficulty breathing, swallowing, or speaking after treatment, since the toxin's effect can rarely spread beyond the treated area.
  • Do not use this treatment during pregnancy or breastfeeding.

References

Source material and product information

  1. Health Canada Product Monograph — IncobotulinumtoxinA

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.